Investments
73Portfolio Exits
25Funds
8Service Providers
1About Nextech Invest
Nextech Invest is a global investment manager founded 1998 and located in Zurich, Switzerland. With its unique oncology-focused funds, Nextech Invest is a dedicated investor in leading oncology companies developing cancer drugs and diagnostics. Nextech Invest benefits from the support of an active and committed Scientific Advisory Board of highly influential oncology advisors, chaired by David Livingston, MD, deputy director at the Dana-Farber Cancer Institute/Harvard Cancer Center.
Want to inform investors similar to Nextech Invest about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Nextech Invest News
Sep 19, 2023
Mariana Oncology – a biotechnology company pioneering a new era of radiopharmaceutical innovation to treat cancers with high unmet needs – recently announced the closing of an oversubscribed $175 million Series B financing co-led by Deep Track Capital and Forbion. Founding investors Atlas Venture, Access Biotechnology, and RA Capital Management are joined by additional new investors Nextech Invest, Surveyor Capital (a Citadel company), and Eli Lilly and Company. The proceeds from the funding will support the advancement of Mariana Oncology’s novel portfolio of precision, next-generation radiopharmaceuticals, including its lead candidate, MC-339, as the company transitions into a clinical-stage organization. In connection with this funding, Rebecca Luse from Deep Track Capital and Geert-Jan Mulder, M.D., from Forbion will join the Board of Directors. KEY QUOTES: “The support of such a strong syndicate of new and existing investors is a testament to Mariana Oncology’s potential. In just 18 months since our Series A, we’ve leveraged our deep expertise in peptide discovery and radiochemistry to advance a diversified portfolio of novel molecules. The proceeds from this financing support the advancement of our pipeline and the initial development of our lead candidate, MC-339, which we anticipate will enter the clinic in 2024 in small cell lung cancer, supported by our own GMP radiopharmaceutical manufacturing.” — Simon Read, Ph.D., Founder and Chief Executive Officer of Mariana Oncology “Radiopharmaceuticals are now being recognized as a logistically viable treatment modality that have demonstrated safety and a high degree of efficacy. These therapies are transforming care for select cancers and are primed to do so across a broader set of indications. Mariana Oncology’s pipeline is innovative and differentiated from most existing radiopharmaceutical companies. We are compelled by the broader opportunity for radiopharmaceuticals beyond prostate cancer and look forward to supporting Mariana Oncology’s success along with their seasoned leadership team and strong syndicate.” — Rebecca Luse of Deep Track Capital “The promising nature of Mariana Oncology’s pipeline is particularly exciting when we look at the possible positive impact on patients. MC-339 has the potential to transform the treatment of small cell lung cancer with the targeted delivery of an actinium payload leveraging the advantages of peptides for enhanced tumoral distribution. We look forward to Mariana Oncology’s evolution into a clinical-stage company with the potential to efficiently deliver an effective new standard of care to patients in the future.” — Geert-Jan Mulder, M.D., Managing Partner of Forbion Trending on Pulse 2.0
Nextech Invest Investments
73 Investments
Nextech Invest has made 73 investments. Their latest investment was in Mariana Oncology as part of their Series B on September 9, 2023.
Nextech Invest Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/7/2023 | Series B | Mariana Oncology | $175M | Yes | 2 | |
6/28/2023 | Series B | K36 Therapeutics | $70M | Yes | Atlas Venture, Bristol Myers Squibb, Eight Roads Ventures, F-Prime Capital, Nextech Invest, and Undisclosed Investors | 1 |
5/16/2023 | Series C | Boundless Bio | $100M | No | Alexandria Venture Investments, ARCH Venture Partners, City Hill Ventures, Fidelity Investments, GT Healthcare Capital Partners, Leaps by Bayer, Logos Capital, Nextech Invest, PFM Health Sciences, Piper Heartland Healthcare Capital, RA Capital Management, Redmile Group, Sectoral Asset Management, Surveyor Capital, Vertex Ventures HC, and Wellington Management | 8 |
3/22/2023 | Series B | |||||
12/14/2022 | Series B |
Date | 9/7/2023 | 6/28/2023 | 5/16/2023 | 3/22/2023 | 12/14/2022 |
|---|---|---|---|---|---|
Round | Series B | Series B | Series C | Series B | Series B |
Company | Mariana Oncology | K36 Therapeutics | Boundless Bio | ||
Amount | $175M | $70M | $100M | ||
New? | Yes | Yes | No | ||
Co-Investors | Atlas Venture, Bristol Myers Squibb, Eight Roads Ventures, F-Prime Capital, Nextech Invest, and Undisclosed Investors | Alexandria Venture Investments, ARCH Venture Partners, City Hill Ventures, Fidelity Investments, GT Healthcare Capital Partners, Leaps by Bayer, Logos Capital, Nextech Invest, PFM Health Sciences, Piper Heartland Healthcare Capital, RA Capital Management, Redmile Group, Sectoral Asset Management, Surveyor Capital, Vertex Ventures HC, and Wellington Management | |||
Sources | 2 | 1 | 8 |
Nextech Invest Portfolio Exits
25 Portfolio Exits
Nextech Invest has 25 portfolio exits. Their latest portfolio exit was EQRx on December 17, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/17/2021 | Reverse Merger | 16 | |||
9/15/2021 | IPO | Public | 8 | ||
8/5/2021 | Acquired | 13 | |||
Date | 12/17/2021 | 9/15/2021 | 8/5/2021 | ||
|---|---|---|---|---|---|
Exit | Reverse Merger | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 16 | 8 | 13 |
Nextech Invest Fund History
8 Fund Histories
Nextech Invest has 8 funds, including Nextech V Oncology.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
9/20/2017 | Nextech V Oncology | Multi-Stage Venture Capital | Closed | $47M | 1 |
7/20/2016 | Oncology IV | ||||
12/31/2011 | Nextech III Oncology LP | ||||
9/30/2008 | Nextech Venture II LP | ||||
5/27/2008 | ONC Partners LP |
Closing Date | 9/20/2017 | 7/20/2016 | 12/31/2011 | 9/30/2008 | 5/27/2008 |
|---|---|---|---|---|---|
Fund | Nextech V Oncology | Oncology IV | Nextech III Oncology LP | Nextech Venture II LP | ONC Partners LP |
Fund Type | Multi-Stage Venture Capital | ||||
Status | Closed | ||||
Amount | $47M | ||||
Sources | 1 |
Nextech Invest Service Providers
1 Service Provider
Nextech Invest has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Counsel | General Counsel |
Service Provider | |
|---|---|
Associated Rounds | |
Provider Type | Counsel |
Service Type | General Counsel |
Partnership data by VentureSource
Nextech Invest Team
7 Team Members
Nextech Invest has 7 team members, including , .
Name | Work History | Title | Status |
|---|---|---|---|
Alfred Scheidegger | >>venture>>, ETH Zurich, CSCS, and Novartis | Founder | Current |
Name | Alfred Scheidegger | ||||
|---|---|---|---|---|---|
Work History | >>venture>>, ETH Zurich, CSCS, and Novartis | ||||
Title | Founder | ||||
Status | Current |
Compare Nextech Invest to Competitors
Corp.m2m Imaging, with offices in USA and Australia produce's high-definition imaging and work flow solutions for life science applications in the MRI, PET, CT and SPECT analytical, preclinical and clinical research environments. m2m's MRI coil and accessory portfolio consists of products that have provided solutions to enable otherwise unobtainable results for research applications all over the world.
Punjab Biotechnology Incubator (PBTI) welcomes users to its state-of-the- art Agri & Food Testing Laboratory set up at SAS Nagar (Mohali), the hub of Biotechnology and Information Technology in Punjab. PBTI is a State Govt. Undertaking registered as a "˜Society for Biotechnology Incubator' under the Society Registration Act 1961 and is professionally governed by Governing Council of the Society under the chairmanship of Chief Secretary, Govt. of Punjab. The day to day affairs are managed by Chief Executive Officer, supported by technical professionals of high caliber.
Chalex Corporation's precision-made chambered McMaster counting slides are used by researchers, laboratories, nematologists and veterinary practitioners throughout the world. Made of clear durable acrylic for long-lasting use, the company's slides also feature exact volumes thanks to injection-molded accuracy which yield consistent test results compared to other slides with handmade chamber spacers. The quality of these slides make them the standard the world over.
Sage Science develops products for the life sciences research markets. Its mission is to provide new systems to streamline and improve sample preparation workflows for DNA and protein analysis.
RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. RegeneMed possesses patented, proprietary, core technologies enabling the in vitro growth of engineered human tissues, including liver, GI tract, bone marrow and blood-brain barrier. These tissue-based in vitro model systems will accelerate drug development and aims to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry, per the company.
Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
